EPRX

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026. Jefferies Global Healthcare Conference1x1 Meetings: June 3rd and 4th Presentation Date & Time: June 3rd, 2026, at 5:30PM – 6:00PM ETLocation: New York, NYWebcast registration link: https://event.summitcast.com/view/N

Stifel initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $25.00

SCHEDULE 13G/A - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications Well-capitalized into H2 2028, beyond key catalysts with over $140 million cash VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the first quarter of 2026. "Th

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation and tissue architecture (which is a measure of fibrosis)EoEHSS sub scores for inflammation demonstrated improvements in all reported cohorts at both 12 weeks (n=31) and 36 weeks (n=27)EoEHSS sub scores for tissue architecture (fibrosis) demonstrated improvements across most reported cohorts at 12 and 36 weeksThe largest response in both the inflammatory and the architectural (fibrosis) sub scores was seen at the highest dose tested VANCOUVER, British Columbia, May 06, 2026 (GLOBE NEWSWIRE

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

EREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus EREFS data reported by Eupraxia demonstrated a relationship between the number of injections of EP-104GI and the overall improvements in the EREFS findings A consistent response in both the inflammatory and fibrotic sub scores of EREFS was demonstrated for patients who received 20 injections. This also represents the number of injections being studied in the placebo-controlled Phase 2b portion of the RESOLVE trial VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals I

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO) as well as the retirement of Dr. Mark Kowalski, Eupraxia's current CMO. Dr. Jeymi Tambiah (MB ChB, FRCS, MS, FAPCR, FFPM), is a Board Certified Cardiothoracic Surgeon physician scientist who practiced at Guys and St Thomas' Hospitals prior to entering the biopharmaceutical in

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company will present 4 abstracts at Digestive Disease Week ("DDW") Annual meeting being held May 2-5, 2026 in Chicago, Illinois. Clinical data will be presented from the ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis ("EoE"). Oral Presentation: Lecture Session: EoE: Advances in Managemen

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia's RESOLVE trial. At 36 weeks, patients in Cohort 9 (n=3) demonstrated a robust response in both tissue health and symptom response compared to their baseline levels.Patients in Cohort 9 also demonstrated the highest response in tissue health at week 36 compared to all other dose cohorts in the RESOLVE trial.Clinical remission in symptoms was maintained in 66% of the patients (2 of 3) in Cohort 9 at week 36. This level of remission was first achieved at week 8 and was maintained through 36 weeks.EP-104GI continues to be well tolerated by patie

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VICTORIA, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will present and participate at the following upcoming investor conferences: Raymond James Biotech Innovation SymposiumFormat: 1x1 MeetingsDate: April 14, 2026Location: New York, NY 2026 Bloom Burton & Co. Healthcare Investor ConferenceFormat: Presentation & 1x1 MeetingsDate: April 21 - 22, 2026Presentatio

William Blair initiated coverage of Eupraxia Pharmaceuticals with a rating of Outperform

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of the RESOLVE trial. The data is important because it is from one of the two doses that are being studied in the placebo-controlled Phase 2b portion of the study.Patients in the highest dose cohort (n=3) had an average reduction of 4 points in their symptom scores compared to baseline (as measured by SDI, where a 3 point reduction is clinical remission).Across dose cohorts 4-9, the decrease in symptom response is the highest at 24 weeks, compared to earlier timepoints. This underlines the value of continuous and steady steroid exposure to reduce infl

40-F - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)